Innovent and Daiichi Sankyo Partner for Vanflyta Commercialisation in China
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialise Vanflyta in China, expanding access for FLT3-ITD positive AML patients.
QuANTUM-First Trial | 11/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy